Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro - PubMed (original) (raw)
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro
Adam Schayowitz et al. Mol Cancer Ther. 2008 Jan.
Abstract
This study was carried out to determine the mechanisms associated with loss of androgen dependency and disease progression in prostate cancer. We investigated the role of the androgen receptor and its relationship to other signal transduction proteins. A hormone-refractory prostate cancer cell line [high-passage LNCaP (HP-LNCaP)] was established in vitro. Cells were treated with inhibitors of mammalian target of rapamycin and tyrosine kinase receptors. Expression of these proteins and the androgen receptor were measured by Western immunoblotting. Analysis of the model and various treatments was also assessed through proliferation assays, luciferase activation assays, binding assays, and ELISA. Our novel antiandrogen, VN/124-1, effectively inhibited proliferation of hormone-resistant prostate cancer cell lines (HP-LNCaP), which were no longer sensitive to bicalutamide and had increased expression of the androgen receptor. Treatment with everolimus or gefitinib resulted in an increase in protein expression and activation of the androgen receptor. Conversely, inhibition of the androgen receptor resulted in increased expression of IGFR1beta, pHER2, pmTOR, and pAkt. The addition of bicalutamide to everolimus or gefitinib inhibited cell proliferation in HP-LNCaP cells. However, the addition of VN/124-1 has proven to be superior to bicalutamide, and the combination was synergistic (P<0.05) compared with either agent alone. This study suggests that compensatory cross-talk between the androgen receptor and various signaling pathways may account for decreased sensitivity to androgen receptor antagonists and the progression to hormone-resistant prostate cancer. Furthermore, these findings suggest that inhibition of both pathways may provide effective control in hormone-resistant prostate cancer and restore sensitivity to androgen antagonists in hormone-refractory patients.
Similar articles
- Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM. Schayowitz A, et al. Br J Cancer. 2010 Sep 28;103(7):1001-7. doi: 10.1038/sj.bjc.6605882. Epub 2010 Sep 14. Br J Cancer. 2010. PMID: 20842117 Free PMC article. - Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI. Ghosh PM, et al. Endocr Relat Cancer. 2005 Mar;12(1):119-34. doi: 10.1677/erc.1.00835. Endocr Relat Cancer. 2005. PMID: 15788644 - The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z. Hobisch A, et al. Prostate. 2006 Mar 1;66(4):413-20. doi: 10.1002/pros.20365. Prostate. 2006. PMID: 16302272 - HER-2/neu receptor in prostate cancer development and progression to androgen independence.
Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, De Placido S. Di Lorenzo G, et al. Tumori. 2004 Mar-Apr;90(2):163-70. doi: 10.1177/030089160409000201. Tumori. 2004. PMID: 15237576 Review. - RAS pathways in prostate cancer - mediators of hormone resistance?
Whitaker HC, Neal DE. Whitaker HC, et al. Curr Cancer Drug Targets. 2010 Dec;10(8):834-9. doi: 10.2174/156800910793358005. Curr Cancer Drug Targets. 2010. PMID: 20718703 Review.
Cited by
- Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.
Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy VP, Njar VC. Kwegyir-Afful AK, et al. Oncotarget. 2015 Sep 29;6(29):27440-60. doi: 10.18632/oncotarget.4578. Oncotarget. 2015. PMID: 26196320 Free PMC article. - Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC. Purushottamachar P, et al. J Med Chem. 2013 Jun 27;56(12):4880-98. doi: 10.1021/jm400048v. Epub 2013 Jun 7. J Med Chem. 2013. PMID: 23713567 Free PMC article. - Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgens.
Shi Q, Wada K, Ohkoshi E, Lin L, Huang R, Morris-Natschke SL, Goto M, Lee KH. Shi Q, et al. Bioorg Med Chem. 2012 Jul 1;20(13):4020-31. doi: 10.1016/j.bmc.2012.05.011. Epub 2012 May 15. Bioorg Med Chem. 2012. PMID: 22672984 Free PMC article. - Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.
Hsiao KC, Shih NY, Fang HL, Huang TS, Kuo CC, Chu PY, Hung YM, Chou SW, Yang YY, Chang GC, Liu KJ. Hsiao KC, et al. PLoS One. 2013 Jul 19;8(7):e69354. doi: 10.1371/journal.pone.0069354. Print 2013. PLoS One. 2013. PMID: 23894455 Free PMC article. - Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA. Soifer HS, et al. J Biol Chem. 2012 Feb 3;287(6):3777-87. doi: 10.1074/jbc.M111.261933. Epub 2011 Dec 15. J Biol Chem. 2012. PMID: 22174412 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous